OEM solutions

Get your solution to your customers faster with lower development costs

Every OEM project is different and has unique go-to-market requirements. Our OEM team has the expertise to work with you on these requirements and develop the best solution.

Our OEM solutions include supplying magnetic beads needed for nucleic acid isolation, components for your custom NGS library, immunoassay technology including ChLIA instrumentation, automating your complete workflow, and many more. With our diverse capabilities, we can significantly reduce your development and manufacturing costs. Whether your business needs a solution that includes a reagent, a complete kit, an OEM liquid handling workstation, or the automation of a complete workflow, we can help. We have over 80 years of experience helping bring products to market efficiently.

OEM complete workflow solutions

We have extensive experience working with customers and collaborators to develop complete solutions to scientific workflows. With our automated solutions for nucleic acid extraction, qualitative and quantitation nucleic acid and protein analysis, liquid handling automation, plate movement and plate handling capabilities, we can provide scientific and engineering technical expertise. You will have an ally who understands your underlying science and can deliver application and solution support for every step of your workflow.

OEM immunoassay technology

Immunoassay developers are able to achieve twin benefits of full automation and improved assay performance by moving from ELISA plates to chemiluminescent beads on IDS open platforms. The random-access ChLIA instrumentation can run multiple assay formats, from chemiluminescence to enzymatic tests, colorimetric tests or simple wet chemistry, to offer developers full flexibility to automate their assays whilst improving performance. Services range from a simple open development platform for R&D, to full commercial instruments and consumables marketed under own-brand livery. Contract assay manufacturing is also available to aid commercial scale-up.

OEM reagents

Our OEM reagent portfolio includes reagents for cell-free DNA isolation from plasma and serum, library preparation kits and kit components, sequencing adapters, and chemagen’s novel M-PVA magnetic beads. Our offerings include a number of patent-pending and patent protected kits and reagents which are available exclusively from us.

Case study

Volition Nu.Q immunoassay development and automation on the IDS-i10 platform

Volition is a multinational diagnostics company that developed the Nucleosomics™ immunoassay platform to profile the epigenetic features of circulating extracellular nucleosomes for early-stage cancer detection. Volition Nu.Q^™ immunoassays run on the Nucleosomics platform can identify individuals who are at risk for colorectal cancer, lung cancer, and a range of blood cancers. The performance of Nu.Q assays improved significantly when Volition transitioned them to the IDS-i10^™ platform of Immunodiagnostic Systems, coupling its biomolecules to magnetic beads, and the company was able to reach its launch targets. Nu.Q immunoassays were originally developed to be run in standard 96-well plates. While the plate format worked well, the company’s nucleosome profiling approach required a step change in development throughput. By partnering with IDS, Volition was able to reduce its limits of detection (LODs) and limits of quantitation (LOQs) by nearly an order of magnitude. They also saw a 5-fold improvement in precision and less inter-day variability. The plate-based assays required 5 hours for one person to run, with a maximum throughput of ~120 samples per day. The bead-based assays can be run in 45 minutes, so 60–80 tests can be performed in one hour. The dynamic range of the chemiluminescent assays is also wider, so fewer dilutions are necessary when biomarker abundance is high.

“Volition was able to scale up quickly and reach its target of developing and analytically validating four new Nu.Q assays per quarter, all while adhering to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). Transitioning from our plate-based RUO format to magnetic beads coupled with the open-access IDS-i10 platform has been transformational in terms of the speed with which we can develop and validate new assays in our discovery pipeline. The combination provides a seamless link from Nu.Q biomarker discovery to clinical test validation through regulatory approval and market launch for our products."